TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04808505: An Open-label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa/Miglustat in Both ERT-experienced and ERT-naïve Pediatric Subjects With Infantile-onset Pompe Disease Aged 0 to < 18 Years

Sponsor: Amicus Therapeutics · Phase: PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 36 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$1,974,510

Rescue Site Savings

+$1,316,340

Unlock Full NCT04808505 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04808505 Rescue Dossier →